Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock

Antiviral Research

Volumn 78, Issue 1, 2008, Pages 170-178

  Goris, Nesya ^a   Vandenbussche, Frank ^a   De Clercq, Kris ^a  

^a VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

Author keywords

African horse sickness; Antiviral; Avian influenza; Bluetongue; Classical swine fever; Control; Foot and mouth disease; Livestock; Newcastle disease; Peste des petits ruminants; Rift Valley fever; Rinderpest; RNA virus; Stamping out; Swine vesicular disease; Vaccination; Vesicular stomatitis

Indexed keywords

2' C METHYLCYTIDINE; 3 DEAZANEPLANOCIN A; 3 DEAZAURIDINE; 5 [(4 BROMOPHENYL)METHYL] 2 PHENYL 5H IMIDAZO[4,5 C]PYRIDINE; ANTIVIRUS AGENT; AZACITIDINE; CPG OLIGODEOXYNUCLEOTIDE; DEZAGUANINE; ENVIROXIME; FLUOROURACIL; INTERFERON; NEPLANOCIN A; NEUTRALIZING ANTIBODY; PLECONARIL; POLYADENYLIC POLYURIDYLIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; PYRAZINAMIDE; RIBAVIRIN; RUPINTRIVIR; T 1105; TBZE 1; UNCLASSIFIED DRUG; VALOPICITABINE;

ANIMAL DISEASE; ARTICLE; DRUG EFFECT; DRUG EFFICACY; FOOT AND MOUTH DISEASE; HEMORRHAGIC FEVER; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; LIVESTOCK; NONHUMAN; PRIORITY JOURNAL; SHEEP DISEASE; VACCINATION; VIRUS INFECTION;

ANIMALS; ANIMALS, DOMESTIC; ANTIVIRAL AGENTS; CATTLE; CHEMOPREVENTION; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; RNA VIRUS INFECTIONS; RNA VIRUSES; VIRAL VACCINES;

ANIMALIA; AVES; EQUIDAE; PESTE-DES-PETITS-RUMINANTS VIRUS; RNA VIRUSES; SUIDAE;

EID: 40749104131     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.10.003     Document Type: Article

References (94)

1. Airaksinen A., Pariente N., Menéndez-Arias L., and Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311 (2003) 339-349
2. Amadori M., Bugnetti M., and Tironi D. Induction and characterisation of swine beta interferon. Comp. Immunol. Microbiol. Infect. Dis. 10 (1987) 71-78
3. Bachrach H.L. Foot-and-mouth disease and its antigens. Adv. Exp. Med. Biol. 185 (1985) 27-46
4. Baker P.J., Harris S., and Webbon C.C. Effect of British hunting ban on fox numbers. Nature 419 (2002) 34
5. Barik S. Control of nonsegmented negative-strand RNA virus replication by siRNA. Virus Res. 102 (2004) 27-35
6. Barteling S.J., and Sutmoller P. Culling versus vaccination: challenging a dogma in veterinary (FMD) science. Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot and Mouth Disease. Izmir, Turkey, FAO, Rome, September 17-20 (2002) (appendix 15)
7. Basu M., Maitra R.K., Xiang Y., Meng X., Banerjee A.K., and Bose S. Inhibition of vesicular stomatitis virus infection in epithelial cells by alpha interferon-induced soluble secreted proteins. J. Gen. Virol. 87 (2006) 2653-2662
8. Belsham G.J. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Prog. Biophys. Mol. Biol. 60 (1993) 241-260
9. Belton D.J. The macro-economic impact of a foot-and-mouth disease incursion in New Zealand. In: Shudel A., and Lombard M. (Eds). Control of Infectious Animal Diseases by Vaccination. Developments in Biologicals vol. 119 (2004), Basel, Krager 457-461
10. Bergmann I.E., Malirat V., Neitzert E., Panizutti N., Sanchez C., and Falczuk A. Improvement of serodiagnostic strategy for foot and mouth disease virus surveillance in cattle under systematic vaccination: a combined system of an indirect ELISA-3ABC with an enzyme-linked immunoelectrotransfer blot. Arch. Virol. 145 (2000) 473-489
11. Bréard E., Sailleau C., Coupier H., Mure-Ravaud K., Hammoumi S., Gicquel B., Hamblin C., Dubourget P., and Zientara S. Comparison of genome segments 2, 7 and 10 of bluetongue viruses serotype 2 for differentiation between field isolates and the vaccine strain. Vet. Res. 34 (2003) 777-789
12. Brocchi E., Bergmann I.E., Dekker A., Paton D.J., Sammin D.J., Greiner M., Grazioli S., De Simone F., Yadin H., Haas B., Bulut N., Malirat V., Neitzert E., Goris N., Parida S., Sorensen K., and De Clercq K. Comparative evaluation of six ELISAs for the detection of antibodies to the non-structural proteins of foot-and-mouth disease virus. Vaccine 24 (2006) 6966-6979
13. Campbell I.D., and Lee R. Carnage by computer: the blackboard economics of the 2001 foot and mouth epidemic. Social Legal Stud. 12 (2003) 425-458
14. Canonico P.G., Jahrling P.B., and Pannier W.L. Antiviral efficacy of pyrazofurin against selected RNA viruses. Antiviral Res. 2 (1982) 331-337
15. Chen W., Yan W., Du O., Fei L., Liu M., Ni Z., Sheng Z., and Zheng Z. RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice. J. Virol. 78 (2004) 6900-6907
16. Chen W., Liu M., Jiao Y., Yan W., Wei X., Chen J., Fei L., Liu Y., Zuo X., Yang F., Lu Y., and Zheng Z. Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. J. Virol. 80 (2006) 3559-3566
17. Chinsangaram J., Moraes M.P., Koster M., and Grubman M.J. Novel viral disease strategy: adenovirus-expressed alpha interferon rapidly protects swine from foot-and-mouth disease. J. Virol. 77 (2003) 1621-1625
18. Coen M.L., Ellis J.A., O'Toole D.T., and Wilson W.C. Cytokine modulation of the interaction between bluetongue virus and endothelial cells in vitro. Vet. Pathol. 28 (1991) 524-532
19. Condy J.B., and Hedger R.S. Experiences in the establishment of a herd of foot-and-mouth disease free African buffalo (Syncerus caffer). S. Afr. J. Wildl. Res. 8 (1978) 87-89
20. Cox S.J., Barnett P.V., Dani P., and Salt J.S. Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 17 (1999) 1858-1868
21. Cox S.J., Voyce C., Parida S., Reid S.M., Hamblin P.A., Paton D.J., and Barnett P.V. Protection against direct-contact challenge following emergency FMD vaccination of cattle and the effect on virus excretion from the oropharynx. Vaccine 23 (2005) 1106-1113
22. Crotty S., Cameron C., and Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis?. J. Mol. Med. 80 (2002) 86-95
23. Cunliffe H.R., Richmond J.Y., and Campbell C.H. Interferon inducers and foot-and-mouth disease vaccines: influence of two synthetic polynucleotides on antibody response and immunity in guinea pigs and swine. Can. J. Comp. Med. 41 (1977) 117-121
24. De Clercq E. Antiviral agents active against influenza A viruses. Nature 5 (2006) 1015-1025
25. De Clercq E., Cools M., Balzarini J., Marquez V.E., Borcherding D.R., Borchardt R.T., Drach J.C., Kitaoka S., and Konno T. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivates. Antimicrob. Agents chemother. 33 (1989) 1291-1297
26. De Clercq E., and Neyts J. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol. Sci. 28 (2007) 280-285
27. De Clercq K., and Goris N. Extending the foot-and-mouth disease module to the control of other diseases. In: Shudel A., and Lombard M. (Eds). Control of Infectious Animal Diseases by Vaccination. Developments in Biologicals vol. 119 (2004), Basel, Krager 333-340
28. Dekker A. Swine vesicular disease, studies on pathogenesis, diagnosis, and epizootiology: a review. Vet. Quart. 22 (2000) 189-192
29. De la Torre J.C., Alarcón B., Martínez-Salas E., Carrasco L., and Domingo E. Ribavirin cures cells of a persistent infection with foot-and-mouth disease virus in vitro. J. Virol. 61 (1987) 233-235
30. de los Santos T., Wu Q., de Avila Botton S., and Grubman M.J. Short hairpin RNA targeted to the highly conserved 2B nonstructural protein coding region inhibits replication of multiple serotypes of foot-and-mouth disease virus. Virology 335 (2005) 222-231
31. De Palma A.M., Heggermont W., Leyssen P., Pürstinger G., Wimmer E., De Clercq E., Rao A., Monforte A.-M., Chimirri A., and Neyts J. Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochem. Biophys. Res. Commun. 353 (2007) 628-632
32. Dewulf J., Laevens H., Koenen F., Mintiens K., and de Kruif A. Efficacy of E2-sub-unit marker and C-strain vaccines in reducing horizontal transmission of classical swine fever virus in weaner pigs. Prev. Vet. Med. 65 (2004) 121-133
33. Diallo A. Control of peste des petits ruminants: classical and new generation vaccines. In: Brown F., and Roth J. (Eds). Vaccines for OIE List A and Emerging Animal Diseases. Developments in Biologicals vol. 114 (2003), Basel, Krager 113-119
34. Domenech J., Lubroth J., Eddi C., Martin V., and Roger F. Regional and international approaches on prevention and control of animal transboundary and emerging diseases. Ann. NY Acad. Sci. 1081 (2006) 90-107
35. Domingo E., Escarmis C., Baranowski E., Ruiz-Jarabo C.M., Carrillo E., Nunez J.I., and Sobrino F. Evolution of foot-and-mouth disease virus. Virus Res. 91 (2003) 47-63
36. Domingo E., Pariente N., Airaksinen A., González-Lopez C., Sierra S., Herrera M., Grande-Pérez A., Lowenstein P.R., Manrubia S.C., Lázaro E., and Escarmís C. Foot-and-mouth disease virus evolution: exploring pathways towards virus extinction. CTMI 288 (2005) 149-173
37. Donaldson A.I. Global FMD situation during 2001. Report of the 67th Session of the Executive Committee of the Standing Technical Committee of the European Commission for the Control of Foot and Mouth Disease. Budapest, Hungary, FAO, Rome, April 25-26 (2002) (appendix 03)
38. Eblé P.L., de Bruin M.G., Bouma A., van Hemert-Kluitenberg F., and Dekker A. Comparison of immune responses after intra-typic heterologous and homologous vaccination against foot-and-mouth disease virus infection in pigs. Vaccine 24 (2006) 1274-1281
39. El-Sabbagh O.I., El-Sadek M.E., El-Kalyoubi S., and Ismail I. Synthesis, DNA binding and antiviral activity of new uracil, xanthine, and pteridine derivates. Arch. Pharm. (Weinheim) 340 (2007) 26-31
40. Floegel-Niesmann G. Marker vaccines and compagnion diagnostic tests for classical swine fever. In: Brown F., and Roth J. (Eds). Vaccines for OIE List A and Emerging Animal Diseases. Developments in Biologicals vol. 114 (2003), Basel, Krager 185-191
41. Food and Agriculture Organization of the United Nations (FAO), 2006. Livestock Report 2006. Available at: http://www.fao.org/docrep/009/a0255e/a0255e00.htm.
42. Fujisaki Y., Ishii S., and Watanabe M. Role of interferon in protection of rabbits against rinderpest virus. Natl. Inst. Anim. Health Q (Tokyo) 8 (1968) 122-131
43. Garner M.G., Fisher B.S., and Murray J.G. Economic aspects of foot and mouth disease: perspectives of a free country, Australia. Rev. Sci. Tech. Off. Int. Epiz. 21 (2002) 625-635
44. Gerdes G.H. Rift Valley fever. Vet. Clin. Food Anim. 18 (2002) 549-555
45. Ghosh A., Nayak R., and Shaila M.S. Inhibition of replication of rinderpest by 5-fluorouracil. Antiviral Res. 31 (1996) 35-44
46. Goebel R.J., Adams A.D., McKernan P.A., Murray B.K., Robins R.K., Revankar G.R., and Canonico P.G. Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides. J. Med. Chem. 25 (1982) 1334-1338
47. Golde W.T., Pacheco J.M., Duque H., Doel T., Penfold B., Ferman G.S., Gregg D.R., and Rodriguez L.L. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23 (2005) 5775-5782
48. Goris N., De Palma A., Toussaint J.-F., Musch I., Neyts J., and De Clercq K. 2′-C-Methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 73 (2007) 161-168
49. Grubman M.J. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antiviral. Biologicals 33 (2005) 227-234
50. Honhold N. The impact of biosecurity on the transmission of FMD in UK in 2001. Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot and Mouth Disease. Paphos, Cyprus, FAO, Rome, October 16-20 (2006)
51. House J.A., House C., Dubourget P., and Lombard M. Protective immunity in cattle vaccinated with a commercial scale, inactivated, bivalent vesicular stomatitis vaccine. Vaccine 21 (2003) 1932-1937
52. Hugh-Jones M.E. Some effects of foot and mouth disease in Brasilian cattle. Second International Symposium on Veterinary Epidemiology and Economics. Canberra, Canada (1979)
53. Kamstrup S., Frimann T.H., and Barfoed A.M. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. Antiviral Res. 72 (2006) 42-48
54. Kitching R.P., and Alexandersen S. Clinical variation in foot and mouth disease: pigs. Rev. Sci. Tech. Off. Int. Epiz. 21 (2002) 513-518
55. Lubroth J., Rweyemamu M.M., Viljoen G., Diallo A., Dungu B., and Amanfu W. Veterinary vaccines and their use in developing countries. Rev. Sci. Tech. Off. Int. Epiz. 26 (2007) 179-201
56. Monaco F., Camma C., Serini S., and Savini G. Differentiation between field and vaccine strain of bluetongue virus serotype 16. Vet. Microbiol. 116 (2006) 45-52
57. Moraes M.P., Chinsangaram J., Brum M.C., and Grubman M.J. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 22 (2003) 268-279
58. Moraes M.P., de Los Santos T., Koster M., Turecek T., Wang H., Andreyev V.G., and Grubman M.J. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J. Virol. 81 (2007) 7124-7135
59. Nerlich, B., Hamilton, C.A., Rowe, V., 2002. Conceptualising foot and mouth disease: the socio-cultural role of metaphors, frames and narratives. Metaphorik.de 02/2002. Available at: http://www.metaphorik.de/02/nerlich.htm.
60. Orsel K., Dekker A., Bouma A., Stegeman J.A., and de Jong M.C. Vaccination against foot and mouth disease reduces virus transmission in groups of calves. Vaccine 23 (2005) 4887-4894
61. Orsel K., de Jong M.C., Bouma A., Stegeman J.A., and Dekker A. The effect of vaccination on foot and mouth disease virus transmission among dairy cows. Vaccine 25 (2007) 327-335
62. Paarlberg P.L., Lee J.G., and Seitzinger A.H. Potential revenue impact of an outbreak of foot-and-mouth disease in the United States. JAVMA 220 (2002) 988-992
63. Pacheco J.M., Brum M.C., Moraes M.P., Golde W.T., and Grubman M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 337 (2005) 205-209
64. Paeshuyse J., Leyssen P., Mabery E., Boddeker N., Vrancken R., Froeyen M., Ansari I.H., Dutartre H., Rozenski J., Gil L.H., Letellier C., Lanford R., Canard B., Koenen F., Kerkhofs P., Donis R.O., Herdewijn P., Watson J., De Clercq E., Puerstinger G., and Neyts J. A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase. J. Virol. 80 (2006) 149-160
65. Pariente N., Sierra S., and Airaksinen A. Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res. 107 (2005) 183-193
66. Paton D.J., Valacher J.-F., Bergmann I., Matlho O.G., Zakharov V.M., Palma E.L., and Thomson G.R. Selection of foot and mouth disease vaccine strains-a review. Rev. Sci. Tech. Off. Int. Epiz. 24 (2005) 981-993
67. Paton D.J., De Clercq K., Greiner M., Dekker A., Brocchi E., Bergmann I., Sammin D.J., Gubbins S., and Parida S. Application of non-structural protein antibody tests in substantiating freedom from foot-and-mouth disease virus infection after emergency vaccination of cattle. Vaccine 24 (2006) 6503-6512
68. Perry B.D., and Rich K.M. Poverty impacts of foot-and-mouth disease and the poverty reduction implications of its control. Vet. Rec. 16 (2007) 238-241
69. Perry B., and Sones K. Science for development. Poverty reduction through animal health. Science 315 (2007) 333-334
70. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., and Stephen E.L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 6 (1986) 285-297
71. Program for Monitoring Emerging Diseases (ProMED-mail), 2007. Foot & mouth disease, zoo wildlife-India (Kerala). ProMED-mail 15 July, 2007; 20070715.2270. http://www.promedmail.org. Accessed July 16, 2007.
72. Roeder P.L., and Taylor W.P. Rinderpest. Vet. Clin. Food Anim. 18 (2002) 515-547
73. Sakamoto K., Ohashi S., Yamazoe R., Takahashi K., and Furuta Y. The inhibition of FMDV excretion from the infected pigs by an antiviral agent, T-1105. Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot and Mouth Disease. Paphos, Cyprus, FAO, Rome, October 16-20 (2006)
74. Salt J.S., Barnett P.V., Dani P., and Williams L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 16 (1998) 746-754
75. Sarma D.K., Kalita K., and Das S. Outbreak of foot and mouth disease due to virus type 'A' and loss of milk production. Blue Cross Book (2004), Intervet India Pvt. Ltd. pp. 21-23
76. Scudamore J.M. Foot-and-mouth disease outbreak. Vet. Rec. 148 (2001) 318
77. Servan de Almeida R., Keita D., Libeau G., and Albina E. Control of ruminant morbillivirus replication by small interfering RNA. J. Gen. Virol. 88 (2007) 2307-2311
78. Sierra S., Dávila M., Lowenstein P.R., and Domingo E. Response of foot-and-mouth disease to increased mutagenesis. Influence of viral load and fitness in loss of infectivity. J. Virol. 74 (2000) 8316-8323
79. Smee D.F., Sidwell R.W., Clark S.M., Barnett B.B., and Spendlove R.S. Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances. Antimicrob. Agents Chemother. 20 (1981) 533-538
80. Steinfeld H., Gerber P., Wassenaar T., Castel V., Rosales M., and de Haan C. Livestock's Long Shadow. first ed. (2006), FAO, Rome
81. Thompson D., Muriel P., Russell D., Osborne P., Bromley A., Rowland M., Creigh-Tyte S., and Brown C. Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev. Sci. Tech. Off. Int. Epiz. 21 (2002) 675-687
82. Toussaint J.F., Sailleau C., Mast J., Houdart P., Czaplicki G., Demeestere L., VandenBussche F., van Dessel W., Goris N., Bréard E., Bounaadja L., Etienne T., Zientara S., and De Clercq K. Bluetongue in Belgium, 2006. Emerg. Infect. Dis. 13 (2007) 614-616
83. UK Department for International Development (DFID), 2000. Halving world poverty by 2015, economic growth, equity and security. Strategies for achieving the international development targets. DFID Strategy Paper. Available at: http://www.dfid.gov.uk/Pubs/files/tspeconomic.pdf.
84. Umans S., and Deleu S. MKZ-uitbraak noopt tot herbezinning. KNMvD 126 (2001) 300-301
85. Verdaguer N., Jimenez-Clavero M.A., Fita I., and Ley V. Structure of swine vesicular disease virus: mapping of changes occurring during adaptation of human coxsackie B5 virus to infect swine. J. Virol. 77 (2003) 9780-9789
86. Vrancken R., Paeshuyse J., Haegeman A., Puerstinger G., Froeyen M., Herdewijn P., Kerkhofs P., Neyts J., and Koenen F. Imidazo[4,5-c]pyridines inhibit the in vitro replication of the classical swine fever virus and target the viral polymerase. Antiviral Res. 77 (2008) 114-119
87. Wirblich C., Bhattacharya B., and Roy P. Nonstructural protein 3 of bluetongue virus assists virus release by recruiting ESCRT-I protein Tsg101. J. Virol. 80 (2006) 460-473
88. World Health Organization. Outbreaks of Rift Valley fever in Kenya, Somalia and United Republic of Tanzania, December 2006-April 2007. Wkly Epidemiol. Rec. 82 (2007) 169-178
89. World Organisation for Animal Health. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. fifth ed. (2004), OIE, Paris, France
90. World Organisation for Animal Health (OIE), 2007a. Handistatus II. Available at: http://www.oie.int/hs2/report.asp?lang=en.
91. World Organisation for Animal Health. Terrestrial Animal Health Code. 16 ed. (2007), OIE, Paris, France
92. World Organisation for Animal Health (OIE), 2007c. World Animal Health Information Database Interface. Available at: http://www.oie.int/wahid-prod/public.php?page=home.
93. Wu Q., Brum M.C.S., Caron L., Koster M., and Grubman M.J. Adenovirus-mediated type I interferon expression delays and reduces disease sings in cattle challenged with foot-and-mouth disease virus. J. Interferon Cytokine Res. 23 (2003) 359-368
94. Yang P.C., Chu R.M., Chung W.B., and Sung H.T. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Vet. Rec. 145 (1999) 731-734